AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23611874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mobile telephone text messages (SMS) after discharge from psychiatric hospital, frequency and content chosen by patients, for 12 months.
Number of subjects: 45
Study 23611874 — intervention group
Group type: COMPARATOR
Intervention: Usual care at the discretion of the team (psychiatry and nursing).
Number of subjects: 45
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to cornflakes
Number of subjects: 10
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to rice
Number of subjects: 10
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to yogurt
Number of subjects: 10
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to turkey dinner
Number of subjects: 10
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (2.5 g) added to granola
Number of subjects: 10
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to granola
Number of subjects: 10
Study 21092221 — intervention group
Group type: COMPARATOR
Intervention: Control (no NVP) granola
Number of subjects: 10
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (5 g) added to various foods
Number of subjects: 10
Study 21092221 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP (5 g) in general
Number of subjects: 10
Study 18691987 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg once daily for 6 days
Number of subjects: 18
Study 18691987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15929958 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus as-needed ambulatory oxygen
Number of subjects: 24
Study 15929958 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy plus ambulatory compressed air
Number of subjects: 24
Study 15929958 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (home oxygen therapy with an oxygen concentrator only)
Number of subjects: 24
Study 12912865 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin (0.006%)
Number of subjects: 44
Study 12912865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (menthol 1%)
Number of subjects: 44
Study 10593470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA), n=30
Number of subjects: 60
Study 10593470 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA), n=30
Number of subjects: 60
Study 8887597 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 60% O2 with added external dead space (O2VD)
Number of subjects: 7
Study 1744422 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of molsidomine (n = 11)
Number of subjects: 27
Study 1744422 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of molsidomine (n = 8)
Number of subjects: 27
Study 1744422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 27
Study 7145537 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apneas
Number of subjects: 75
Study 7145537 — intervention group
Group type: COMPARATOR
Intervention: Central sleep apneas
Number of subjects: 75
Study 31626819 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven (Ω3‐FAs)
Number of subjects: 261
Study 31544382 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye acupuncture combined with conventional acupuncture
Number of subjects: 90
Study 31544382 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 90
Study 31544382 — intervention group
Group type: COMPARATOR
Intervention: Western medication (sodium hyaluronate eye drops)
Number of subjects: 90
Study 29237679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg once daily)
Number of subjects: 231
Study 29237679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 25331981 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered parent training with minimal therapist contact (written material and brief weekly telephone consultations)
Number of subjects: 48
Study 25331981 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered parent training
Number of subjects: 48
Study 25331981 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WLC)
Number of subjects: 48
Study 23928735 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE + EAM
Number of subjects: 84
Study 23928735 — intervention group
Group type: COMPARATOR
Intervention: EAM only
Number of subjects: 84
Study 22119521 — intervention group
Group type: COMPARATOR
Intervention: Assessment condition
Number of subjects: 299
Study 22119521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 299
Study 22119521 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness to change
Number of subjects: 299
Study 20969665 — intervention group
Group type: EXPERIMENTAL
Intervention: LGP‐HA+L (large-gel particle hyaluronic acid plus 0.3% lidocaine)
Number of subjects: 60
Study 20969665 — intervention group
Group type: COMPARATOR
Intervention: LGP‐HA (large-gel particle hyaluronic acid without lidocaine)
Number of subjects: 60
Study 17939882 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5%
Number of subjects: 59
Study 17939882 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 0.3%
Number of subjects: 59
Study 16370302 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral laminotomy (Group 1)
Number of subjects: 120
Study 16370302 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laminotomy (Group 2)
Number of subjects: 120
Study 16370302 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy (Group 3)
Number of subjects: 120
Study 11955728 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day (20 milliliters po qAM)
Number of subjects: 56
Study 11955728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 11955728 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) for head-and-neck cancer patients
Number of subjects: 56
Study 11955728 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) for lung cancer patients
Number of subjects: 56
Study 9536950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 15
Study 9536950 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 15
Study 9536950 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for one week)
Number of subjects: 15
Study 9536950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 15
Study 7642012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (Group A)
Number of subjects: 66
Study 7642012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (Group B)
Number of subjects: 66
Study 7642012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 66
Study 7642012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 66
Study 7642012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 66
Study 7642012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide and Sotalol
Number of subjects: 66
Study 1695785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha blockers (e.g., prazosin, terazosin)
Number of subjects: 0
Study 1695785 — intervention group
Group type: COMPARATOR
Intervention: Nonselective alpha blockers (e.g., phenoxybenzamine)
Number of subjects: 0
Study 29806 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergonovine maleate (MEM)
Number of subjects: 200
Study 29806 — intervention group
Group type: COMPARATOR
Intervention: Control (no MEM)
Number of subjects: 200
Study 30654912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation of 4000 IU daily for three years
Number of subjects: 400
Study 30654912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 27564599 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU onabotulinum toxin A (onaBoNT‐A)
Number of subjects: 442
Study 27564599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 24723058 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Number of subjects: 25
Study 21983916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 35
Study 21983916 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (control)
Number of subjects: 35
Study 22105592 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin exposure with contrast media (CM)
Number of subjects: 50
Study 22105592 — intervention group
Group type: COMPARATOR
Intervention: ClCr before CM exposure
Number of subjects: 50
Study 22105592 — intervention group
Group type: COMPARATOR
Intervention: ClCr after CM exposure
Number of subjects: 50
Study 18334122 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidectomy and ipsilateral central lymph node dissection (Group A)
Number of subjects: 84
Study 18334122 — intervention group
Group type: COMPARATOR
Intervention: Thyroidectomy (Group B)
Number of subjects: 84
Study 16365066 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (50 mg/d)
Number of subjects: 89
Study 16365066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fruit cereal bars without soy isoflavones)
Number of subjects: 89
Study 12801622 — intervention group
Group type: EXPERIMENTAL
Intervention: xuezhikang 1200 mg/day (600 mg twice daily)
Number of subjects: 50
Study 12801622 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (control group)
Number of subjects: 50
Study 10950032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 338
Study 10950032 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 338
Study 10950032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 338
Study 10950032 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 338
Study 8836825 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (smoking cessation intervention)
Number of subjects: 349
Study 8836825 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 349
Study 1565785 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid bolus
Number of subjects: 104
Study 1565785 — intervention group
Group type: COMPARATOR
Intervention: Liquid bolus
Number of subjects: 104
Study 2865275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (2.5 mg)
Number of subjects: 6
Study 2865275 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.07 mg/kg IV bolus, maintained by 0.025 to 0.04 mg/kg/hr infusion for eight hours)
Number of subjects: 6
Study 28282996 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training
Number of subjects: 137
Study 28282996 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training with peer-led support
Number of subjects: 137
Study 28282996 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training with peer support
Number of subjects: 137
Study 28282996 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 137
Study 29649248 — intervention group
Group type: COMPARATOR
Intervention: Non-orphaned children
Number of subjects: 370
Study 29649248 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphaned children
Number of subjects: 370
Study 27157027 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational text message intervention adjunct to cognitive-behavioral therapy
Number of subjects: 12
Study 27157027 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational text message intervention
Number of subjects: 12
Study 24830223 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational session
Number of subjects: 69
Study 24830223 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall
Number of subjects: 69
Study 24830223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies together
Number of subjects: 69
Study 24830223 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 22503201 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cerebral perfusion (ACP)
Number of subjects: 25
Study 22503201 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 25
Study 20231242 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-item WISDM (68-item version)
Number of subjects: 0
Study 20231242 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-item WISDM (37-item version)
Number of subjects: 0
Study 18310553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP)
Number of subjects: 60
Study 18310553 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (after receiving TAP)
Number of subjects: 60
Study 15925286 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact (Japan) supplement (1 L/d for 5 days before surgery)
Number of subjects: 26
Study 15925286 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact (Japan) supplement
Number of subjects: 26
Study 15925286 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet (control group)
Number of subjects: 26
Study 15521326 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel controlled-release formulations of niacin based on polyethylene oxide (PEO) and hydroxypropylmethyl cellulose (HPMC) matrices.
Number of subjects: 0
Study 15521326 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC-based matrix system.
Number of subjects: 0
Study 15521326 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation of interest (specific formulation not detailed).
Number of subjects: 0
Study 15521326 — intervention group
Group type: COMPARATOR
Intervention: Commercial product (control).
Number of subjects: 0
Study 11526359 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis (5 treatments)
Number of subjects: 78
Study 11526359 — intervention group
Group type: COMPARATOR
Intervention: Balloon PTCA only / Stents (Control)
Number of subjects: 78
Study 9232448 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch allergen immunotherapy (IT)
Number of subjects: 10
Study 9232448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8453021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 19
Study 8453021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 19
Study 8453021 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized nitroglycerin
Number of subjects: 19
Study 8453021 — intervention group
Group type: COMPARATOR
Intervention: Sublingual and aerosolized nitroglycerin
Number of subjects: 19
Study 3310341 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 168
Study 3310341 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 168
Study 3310341 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 168
Study 31179792 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 3010
Study 31179792 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 3010
Study 31179792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3010
Study 31179792 — intervention group
Group type: COMPARATOR
Intervention: BMI >25
Number of subjects: 3010
Study 31179792 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome
Number of subjects: 3010
Study 31179792 — intervention group
Group type: COMPARATOR
Intervention: PASI score
Number of subjects: 3010
Study 29527709 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 758
Study 29527709 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 758
Study 27247336 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel or ticagrelor
Number of subjects: 203
Study 27247336 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 203
Study 24430319 — intervention group
Group type: COMPARATOR
Intervention: CEA only (n=300)
Number of subjects: 1202
Study 24430319 — intervention group
Group type: COMPARATOR
Intervention: CT only (n=299)
Number of subjects: 1202
Study 24430319 — intervention group
Group type: COMPARATOR
Intervention: CEA+CT (n=302)
Number of subjects: 1202
Study 24430319 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum follow-up (n=301)
Number of subjects: 1202
Study 24430319 — intervention group
Group type: COMPARATOR
Intervention: Combined intensive monitoring groups (CEA, CT, CEA+CT)
Number of subjects: 1202
Study 21519851 — intervention group
Group type: EXPERIMENTAL
Intervention: RTE targeted biopsy
Number of subjects: 139
Study 21519851 — intervention group
Group type: COMPARATOR
Intervention: Random biopsy
Number of subjects: 139
Study 20537815 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment (Drug or Money)
Number of subjects: 11
Study 20537815 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishment (Drug Only+Money Loss)
Number of subjects: 11
Study 20537815 — intervention group
Group type: COMPARATOR
Intervention: Unemployment (Drug Only)
Number of subjects: 11
Study 18950299 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation in patients with valvular cardiomyopathy
Number of subjects: 17
Study 18950299 — intervention group
Group type: COMPARATOR
Intervention: ICD implantation in patients with ischemic cardiomyopathy
Number of subjects: 17
Study 18950299 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation in both groups
Number of subjects: 17
Study 16497309 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14606736 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical motor feedback (MMF) therapy, 15 sessions
Number of subjects: 23
Study 14606736 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait therapy, 15 sessions
Number of subjects: 23
Study 11105402 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 0
Study 11105402 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom lecture (TCL)
Number of subjects: 0
Study 11105402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CAI and TCL
Number of subjects: 0
Study 8872686 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.125 mg/kg injection, propofol 12.5 mcg/kg/min infusion
Number of subjects: 12
Study 8872686 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.25 mg/kg injection, propofol 25 mcg/kg/min infusion
Number of subjects: 12
Study 8872686 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg injection, propofol 50 mcg/kg/min infusion
Number of subjects: 12
Study 8872686 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1.4 mcg/kg injection (positive control)
Number of subjects: 12
Study 8872686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, Intralipid)
Number of subjects: 12
Study 1326277 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose marihuana (2.53% delta 9-tetrahydrocannabinol)
Number of subjects: 15
Study 1326277 — intervention group
Group type: COMPARATOR
Intervention: Placebo marihuana
Number of subjects: 15
Study 1326277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose marihuana (1.26% delta 9-tetrahydrocannabinol)
Number of subjects: 15
Study 3880992 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.50 mg intravenously in 20 minutes)
Number of subjects: 40
Study 3880992 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline solution
Number of subjects: 40
Study 3880992 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 40
Study 31746877 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry (BB) supplementation (1 cup per day)
Number of subjects: 100
Study 31746877 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry (SB) supplementation (2 cups per day)
Number of subjects: 100
Study 31746877 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100
Study 29289658 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0
Study 29289658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26781620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascade (n=25)
Number of subjects: 47
Study 26781620 — intervention group
Group type: COMPARATOR
Intervention: 6-month waitlist (n=22)
Number of subjects: 47
Study 25368995 — intervention group
Group type: EXPERIMENTAL
Intervention: High vibration group (HVG)
Number of subjects: 30
Study 25368995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vibration group (LVG)
Number of subjects: 30
Study 25368995 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 22974804 — intervention group
Group type: EXPERIMENTAL
Intervention: losmapimod 7.5 mg once daily (lower dose)
Number of subjects: 99
Study 22974804 — intervention group
Group type: EXPERIMENTAL
Intervention: losmapimod 7.5 mg twice daily (higher dose)
Number of subjects: 99
Study 19890632 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant poxviral vaccine with GM-CSF
Number of subjects: 32
Study 19890632 — intervention group
Group type: COMPARATOR
Intervention: Recombinant poxviral vaccine without GM-CSF
Number of subjects: 32
Study 19890632 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant poxviral vaccine
Number of subjects: 32
Study 17917313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for 3 months
Number of subjects: 51
Study 17917313 — intervention group
Group type: COMPARATOR
Intervention: No CPAP treatment (control)
Number of subjects: 51
Study 17917313 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 51
Study 17917313 — intervention group
Group type: COMPARATOR
Intervention: Patients with AHI >or=20/h
Number of subjects: 51
Study 15388511 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab 5 mg/kg every 6 weeks
Number of subjects: 52
Study 11826333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane review
Number of subjects: 0